About Carfilzomib API
Therapeutic CategoryAnti-Cancer/ Oncology
CAS Number
868540-17-4
API Technology
Synthetic
Dose Form
Injectable
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, China DMF
Mechanism of Action
Kyprolis (carfilzomib) is a proteasome inhibitor that irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited proteasome activity in blood and tissue and delayed tumor growth.
Indication
KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Related APIs
Abiraterone Acetate
Anti-Cancer/ Oncology
Adagrasib
Anti-Cancer/ Oncology
Apalutamide (Amorphous & Form B)
Anti-Cancer/ Oncology
Azacitidine
Anti-Cancer/ Oncology
Bendamustine Hydrochloride
Anti-Cancer/ Oncology
Bortezomib
Anti-Cancer/ Oncology
Cabazitaxel
Anti-Cancer/ Oncology
Cabozantinib S-Malate
Anti-Cancer/ Oncology
Capecitabine
Anti-Cancer/ Oncology
Carfilzomib
Anti-Cancer/ Oncology
Darolutamide
Anti-Cancer/ Oncology
Dasatinib (Monohydrate)
Anti-Cancer/ Oncology
Decitabine
Anti-Cancer/ Oncology
Deucravacitinib
Anti-Cancer/ Oncology
Fruquintinib
Anti-Cancer/ Oncology
Gemcitabine Hydrochloride
Anti-Cancer/ Oncology
Granisteron
Anti-Cancer/ Oncology
Lenalidomide (Form A)
Anti-Cancer/ Oncology
Lenvatinib Mesylate ( MIBK Solvate)
Anti-Cancer/ Oncology
Lomustine
Anti-Cancer/ Oncology
Midostaurin
Anti-Cancer/ Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Anti-Cancer/ Oncology
Olaparib (Form A)
Anti-Cancer/ Oncology
Palbociclib
Anti-Cancer/ Oncology
Pazopanib
Anti-Cancer/ Oncology
Pemetrexed Disodium Heptahydrate
Anti-Cancer/ Oncology
Pirtobrutinib
Anti-Cancer/ Oncology
Pomalidomide
Anti-Cancer/ Oncology
Relugolix
Anti-Cancer/ Oncology
Ripretinib
Anti-Cancer/ Oncology
Tucatinib
Anti-Cancer/ Oncology
Venetoclax
Anti-Cancer/ Oncology
Zanubrutinib
Anti-Cancer/ Oncology
Zoledronic Acid
Anti-Cancer/ Oncology
Cabozantinib Hydrochloride
Anti-Cancer/ Oncology
Eribulin Mesylate
Anti-Cancer/ Oncology
Enzalutamide (Crystalline & Premix)
Anti-Cancer/ Oncology
Lenvatinib Mesylate (Form-C)
Anti-Cancer/ Oncology
Niraparib Tosylate
Anti-Cancer/ Oncology
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Disclaimer
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.